Surrozen, Inc. (SRZN) NASDAQ

11.36

-0.84(-6.89%)

Updated at September 08 04:00PM

Currency In USD

Surrozen, Inc.

Address

171 Oyster Point Boulevard

South San Francisco, CA 94080

United States of America

Phone

650 489 9000

Sector

Healthcare

Industry

Biotechnology

Employees

40

First IPO Date

January 11, 2021

Key Executives

NameTitlePayYear Born
Mr. Craig C. Parker M.B.A.Chief Executive Officer, President & Director892,3751962
Dr. Li Yang Ph.D.Executive Vice President of Research579,8501969
Mr. Charles WilliamsChief Financial Officer, Chief Operating Officer & Corporate Secretary647,6391980
Dr. Roeland Nusse Ph.D.Co-Founder & Member of Scientific Advisory Board01950
Dr. Calvin Kuo M.D., Ph.D.Co-Founder & Member of Scientific Advisor0N/A
Dr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory Board0N/A
Esther JhunController0N/A

Description

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.